ValuEngine Downgrades Nuvectra (NVTR) to Sell
Nuvectra (NASDAQ:NVTR) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Friday.
Separately, Piper Jaffray Companies reissued a “hold” rating and set a $12.00 price objective on shares of Nuvectra in a research note on Friday, November 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $12.00.
Shares of Nuvectra (NASDAQ:NVTR) traded up $0.16 on Friday, hitting $9.06. 23,613 shares of the company traded hands, compared to its average volume of 66,190. The company has a current ratio of 2.90, a quick ratio of 2.72 and a debt-to-equity ratio of 0.37. Nuvectra has a fifty-two week low of $4.90 and a fifty-two week high of $15.00.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Gilder Gagnon Howe & Co. LLC raised its stake in Nuvectra by 12.5% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 953,431 shares of the company’s stock worth $12,662,000 after purchasing an additional 105,580 shares during the period. EAM Investors LLC purchased a new position in Nuvectra during the second quarter worth approximately $752,000. Hodges Capital Management Inc. raised its stake in Nuvectra by 18.6% during the second quarter. Hodges Capital Management Inc. now owns 227,807 shares of the company’s stock worth $3,025,000 after purchasing an additional 35,706 shares during the period. Dimensional Fund Advisors LP raised its stake in Nuvectra by 4.0% during the third quarter. Dimensional Fund Advisors LP now owns 730,117 shares of the company’s stock worth $9,681,000 after purchasing an additional 28,268 shares during the period. Finally, Vanguard Group Inc. raised its stake in Nuvectra by 6.2% during the second quarter. Vanguard Group Inc. now owns 310,794 shares of the company’s stock worth $4,128,000 after purchasing an additional 18,081 shares during the period. 58.89% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “ValuEngine Downgrades Nuvectra (NVTR) to Sell” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/02/valuengine-downgrades-nuvectra-nvtr-to-sell.html.
Nuvectra Company Profile
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Nuvectra Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra Corporation and related companies with MarketBeat.com's FREE daily email newsletter.